iPSC-based research in ALS precision medicine

Letizia Mazzini; Fabiola De Marchi

doi:10.1016/j.stem.2023.05.008

iPSC-based research in ALS precision medicine

Letizia Mazzini
, Fabiola De Marchi

Risultato della ricerca: Contributo su rivista › Commento

Abstract

Clinical trials in amyotrophic lateral sclerosis (ALS) are challenged by the lack of pre-clinical models and biomarkers of disease onset and progression. In this issue, Morimoto et al. use induced pluripotent stem cell (iPSC)-derived motor neurons from patients with ALS to study therapeutic mechanisms of ropinirole in a clinical trial and identify treatment responders.

Lingua originale	Inglese
pagine (da-a)	748-749
Numero di pagine	2
Rivista	Cell Stem Cell
Volume	30
Numero di pubblicazione	6
DOI	https://doi.org/10.1016/j.stem.2023.05.008
Stato di pubblicazione	Pubblicato - 1 giu 2023
Pubblicato esternamente	Sì

Accesso al documento

10.1016/j.stem.2023.05.008

Altri file e collegamenti

Link to publication in Scopus

Cita questo

@article{f0adb90777e64f3484c473539c7cad3b,

title = "iPSC-based research in ALS precision medicine",

abstract = "Clinical trials in amyotrophic lateral sclerosis (ALS) are challenged by the lack of pre-clinical models and biomarkers of disease onset and progression. In this issue, Morimoto et al. use induced pluripotent stem cell (iPSC)-derived motor neurons from patients with ALS to study therapeutic mechanisms of ropinirole in a clinical trial and identify treatment responders.",

author = "Letizia Mazzini and \{De Marchi\}, Fabiola",

note = "Publisher Copyright: {\textcopyright} 2023 Elsevier Inc.",

year = "2023",

month = jun,

day = "1",

doi = "10.1016/j.stem.2023.05.008",

language = "English",

volume = "30",

pages = "748--749",

journal = "Cell Stem Cell",

issn = "1934-5909",

publisher = "Cell Press",

number = "6",

}

TY - JOUR

T1 - iPSC-based research in ALS precision medicine

AU - Mazzini, Letizia

AU - De Marchi, Fabiola

PY - 2023/6/1

Y1 - 2023/6/1

N2 - Clinical trials in amyotrophic lateral sclerosis (ALS) are challenged by the lack of pre-clinical models and biomarkers of disease onset and progression. In this issue, Morimoto et al. use induced pluripotent stem cell (iPSC)-derived motor neurons from patients with ALS to study therapeutic mechanisms of ropinirole in a clinical trial and identify treatment responders.

AB - Clinical trials in amyotrophic lateral sclerosis (ALS) are challenged by the lack of pre-clinical models and biomarkers of disease onset and progression. In this issue, Morimoto et al. use induced pluripotent stem cell (iPSC)-derived motor neurons from patients with ALS to study therapeutic mechanisms of ropinirole in a clinical trial and identify treatment responders.

UR - https://www.scopus.com/pages/publications/85159886916

U2 - 10.1016/j.stem.2023.05.008

DO - 10.1016/j.stem.2023.05.008

M3 - Comment/debate

SN - 1934-5909

VL - 30

SP - 748

EP - 749

JO - Cell Stem Cell

JF - Cell Stem Cell

IS - 6

ER -

iPSC-based research in ALS precision medicine

Abstract

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo